en · de · es · fr · pt
liraglutide-notes.peptides6608.com › Data › Ipamorelin Background And Pharmacology — Reference Sheet

Ipamorelin Background And Pharmacology — Reference Sheet

By Editorial Desk · published 2025-08-07 · last reviewed 2025-09-15 · Data

peptide purity raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2025-09-15 and is reviewed periodically as new material appears.

Ipamorelin Background and Pharmacology

Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.

At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.

背景与分子特征

在 GHS 家族中,早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放,并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性,对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同,而完整的分子解释仍有待补充。需要区分的是,选择性是研究观察中的相对程度,并非绝对界限。

从用途定位看,ipamorelin 目前主要以研究用肽的身份被讨论,未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用,不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小,因此对其效应强度与一致性的描述应保持谨慎。

Ipamorelin at a glance

PropertyValueNotes
Chemical classSynthetic pentapeptideGrowth hormone secretagogue family
SequenceAib-His-D-2-Nal-D-Phe-Lys-NH2Contains two non-natural residues
Molecular formulaC38H49N9O5Free base form
Molecular weight711.85 g/molCalculated from formula
Primary targetGHS-R1a ghrelin receptorAgonist activity

背景与受体作用机制

现有文献多来自小规模、短期的研究,涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏,以及重复给药后效应是否衰减,仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大,因此结论外推需谨慎。关于临床获益的确切证据尚不充分,需要更大规模的对照试验来澄清。

Ipamorelin 是一种合成五肽,在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路,但并非天然激素。早期药理学研究显示,它可刺激垂体释放生长激素,而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。

Related pages on this site

Analytical Methods and Storage Stability

Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.

Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.

Reference notes

B&O Supprettes is the brand name for a prescription medication containing powdered opium and belladonna alkaloids in a suppository form. They are indicated for the treatment of moderate to severe pain from urethral spasm, and for extending the interval(s) between injections of opiates. The drug has various "off label" uses, including renal colic, intestinal cramps, tenesmus and diarrhea. They are also often prescribed after urinary bladder surgery. B&O Supprettes was unique in the United States because they were the only drug containing opium that is for suppository use sold in the US and, in fact, one of the very few medications that contains opium in any form in the US along with paregoric and opium tincture (laudanum).

== Mechanism of action == As a sulfonamide antibiotic, sulfanilamide functions by competitively inhibiting (that is, by acting as a substrate analogue of) enzymatic reactions involving para-aminobenzoic acid (PABA). Specifically, it competitively inhibits the enzyme dihydropteroate synthase. PABA is needed in enzymatic reactions that produce folic acid, which acts as a coenzyme in the synthesis of purines and pyrimidines. Mammals do not synthesize their own folic acid so are unaffected by PABA inhibitors, which selectively kill bacteria. However, this effect can be reversed by adding the end products of one-carbon transfer reactions, such as thymidine, purines, methionine, and serine. PABA can also reverse the effects of sulfonamides.

All forms of androgen insensitivity, including CAIS, are associated with infertility, though exceptions have been reported for both the mild and partial forms. CAIS is associated with a decreased bone mineral density. Some have hypothesized that the decreased bone mineral density observed in women with CAIS is related to the timing of gonadectomy and inadequate estrogen supplementation. However, recent studies show that bone mineral density is similar whether gonadectomy occurs before or after puberty, and is decreased despite estrogen supplementation, leading some to hypothesize that the deficiency is directly attributable to the role of androgens in bone mineralization. CAIS is also associated with an increased risk for gonadal tumors (e.g. germ cell malignancy) in adulthood if gonadectomy is not performed. The risk of malignant germ cell tumors in women with CAIS increases with age and has been estimated to be 3.6% at 25 years and 33% at 50 years. The incidence of gonadal tumors in childhood is thought to be relatively low; a recent review of the medical literature found that only three cases of malignant germ cell tumors in prepubescent girls have been reported in association with CAIS in the last 100 years. Some have estimated the incidence of germ cell malignancy to be as low as 0.8% before puberty. Vaginal hypoplasia, a relatively frequent finding in CAIS and some forms of PAIS, is associated with sexual difficulties including vaginal penetration difficulties and dyspareunia.

Other compounds other than radiolabelled somatostatin receptor antagonists have also been studied. Cyclosomatostatin is one such compound. Contrary to previously discussed compounds, cyclosomatostatin does not contain a radionuclide. It is a non-selective somatostatin receptor antagonist, inhibiting the effects of somatostatin on target cells in the gastrointestinal tract, pancreas, hypothalamus, and central nervous system. Cyclosomatostatin is used as a research chemical to investigate the effects of somatostatin on different cell types by antagonizing its receptors. However it acts as an agonist in SH-SY5Y neuroblastoma cells. Cyclosomatostatin is also known by the following names:

Sources: en.wikipedia.org

Reference notes

In addition, the contributions of his foundation made possible a project introducing children to marine sciences, aboard the 90-foot research vessel the Robert G. Brownlee, built in 1998 and run by the Marine Science Institute (San Francisco Bay) of Redwood City, California. He died on February 27, 1991, of AIDS.

=== Manga === A manga adaptation of the first part illustrated by Nappa Komatsuda began serialization in Hakusensha's shōjo manga magazine LaLa on July 23, 2022. Its chapters have been collected into eight tankōbon volumes as of July 2026. The manga adaptation is also licensed in English by Yen Press. A spin-off manga illustrated by Yuriko Asami, titled Agents of the Four Seasons: One Hundred Songs and One Hundred Pages (春夏秋冬代行者 百歌百葉, Shunkashūtō Daikōsha Hyakka Hyakuyō) began serialization in the Dengeki G's Comic section of both ComicWalker and Nico Nico Seiga websites on May 15, 2023. Its chapters have been collected into three tankōbon volumes as of May 2026. The spin-off is published in English on Kadokawa's BookWalker website.

C.D.E. See: #Certified diabetes educator. C-peptide A substance the pancreas releases into the bloodstream in equal amounts to insulin. While being stored in pancreatic beta cells, proinsulin includes both insulin and C-peptide, which is freed before insulin secretion into the blood. Currently, since pharmaceutical insulin does not contain C-peptide, a C-peptide level test will show how much insulin the body is making. Insulin is prepared as two insulin molecules linked by a c-peptide. When insulin is secreted, C-peptide is released as well. It has in recent years been shown to have hormone properties, so far chiefly in connection with arterial vessel muscle tone. It has been shown to ameliorate some diabetic complications, such as neuropathy and microvascular damage. C-peptide varies much more between animal species than does insulin itself. Calcium channel blocker Calcium ions are used in many cells, including beta cells, as a signaling mechanism. Since it does not ordinarily pass through cell membranes, protein pores in cell membranes are used to provide a channel through which it can be 'pumped' – an activity which requires energy if done against a concentration gradient. A Ca+ channel blocker is a drug which interferes with the operation of (some?) such channels. They have widespread effects, since Ca+ is used for many purposes in assorted tissues.

=== Coloring in consumer products === Consumer product uses have included incorporation into dental porcelain, used for false teeth to simulate the fluorescence of natural teeth, and uranium-bearing reagents used in chemistry laboratories (e.g. uranyl acetate, used in analytical chemistry and as a stain in electron microscopy). Uranium (both depleted uranium and natural uranium) was widely used as a coloring matter for porcelain and glass in the 19th and early-to-mid-20th century. The practice was largely discontinued in the late 20th century. In 1999, concentrations of 10% depleted uranium were being used in "jaune no.17" a yellow enamel powder that was being produced in France by Cristallerie de Saint-Paul, a manufacturer of enamel pigments. The depleted uranium used in the powder was sold by Cogéma's Pierrelatte facility. In February 2000, Cogema discontinued the sale of depleted uranium to producers of enamel and glass.

Survodutide (BI 456906) is an experimental peptide that works as a dual glucagon/GLP-1 receptor agonist. Unlike other dual GLP-1/glucagon dual agonists, it is a glucagon analog rather than an analog of oxyntomodulin. It is developed by Boehringer Ingelheim as a weight loss drug. Survodutide is a twincretin having dual glucagon-like peptide-1 and glucagon receptor agonist activity, conceptually based on endogenous peptide oxyntomodulin. In a meta-analysis involving data from 3 randomized controlled trials having 1088 patients, 4- 11 months use of survodutide at doses 2.4-4.8 mg / week was associated with on an average 7-9% reduction in body weight from baseline. This translates to around 9-15kg of body weight reduction from baseline. Gastrointestinal side effects were the predominant side effects, were mild and dose dependent, as has been noted with other incretin based therapies. In adults with obesity and at-risk MASLD, survodutide was statistically and clinically superior to placebo in reducing MRI-PDFF–assessed liver fat content (LFC) and body weight.

Sources: en.wikipedia.org

Reference notes

== Adulteration, contamination and mislabeling == Over the period 2008 to 2011, the Government Accountability Office (GAO) of the United States received 6,307 reports of health problems (identified as adverse events) from use of dietary supplements containing a combination of ingredients in manufactured vitamins, minerals or other supplement products, with 92% of tested herbal supplements containing lead and 80% containing other chemical contaminants. Using undercover staff, the GAO also found that supplement retailers intentionally engaged in "unequivocal deception" to sell products advertised with baseless health claims, particularly to elderly consumers. Consumer Reports also reported unsafe levels of arsenic, cadmium, lead and mercury in several protein powder products. The Canadian Broadcasting Corporation (CBC) reported that protein spiking, i.e., the addition of amino acids to manipulate protein content analysis, was common. Many of the companies involved challenged CBC's claim. In some botanical products, undeclared ingredients were used to increase the bulk of the product and reduce its cost of manufacturing, while potentially violating certain religious and/or cultural limitations on consuming animal ingredients, such as cow, buffalo or deer. In 2015, the New York Attorney General (NY-AG) identified four major retailers with dietary supplement products that contained fraudulent and potentially dangerous ingredients, requiring the companies to remove the products from retail stores.

== French domestic situation == The 1946 Constitution creating the Fourth Republic (1946–1958) made France a parliamentary republic. Because of the political context, it could find stability only by an alliance between the three dominant parties: the Christian Democratic Popular Republican Movement (MRP), the French Communist Party (PCF) and the socialist French Section of the Workers' International (SFIO). Known as tripartisme, this alliance briefly lasted until the May 1947 crisis, with the expulsion from Paul Ramadier's SFIO government of the PCF ministers, marking the official start of the Cold War in France. This had the effect of weakening the regime, with the two most significant movements of this period, Communism and Gaullism, in opposition. A strong anti-war movement came into existence in France driven mostly by the powerful French Communist Party (outpowering the socialists) and its young militant associations, major trade unions such as the General Confederation of Labour, and notable leftist intellectuals. The first occurrence was probably at the National Assembly on March 21, 1947, when the communist deputies refused to back the military credits for Indochina. The following year a pacifist event was organized, the "1st Worldwide Congress of Peace Partisans" (1er Congrès Mondial des Partisans de la Paix, the World Peace Council's predecessor), which took place March 25–28, 1948, in Paris, with the French communist Nobel laureate atomic physicist Frédéric Joliot-Curie as president.

Building trust and acceptance of a licensed vaccine among the public is a task of communication by governments and healthcare personnel to ensure a vaccination campaign proceeds smoothly, saves lives, and enables economic recovery. When a vaccine is licensed, it will initially be in limited supply due to variable manufacturing, distribution, and logistical factors, requiring an allocation plan for the limited supply and which population segments should be prioritized to first receive the vaccine.

== History == D-dimer was originally identified, described and named in 1973, at the National Institute for Medical Research in Mill Hill, Greater London. It found its diagnostic application in the 2000s. Its use has now been formalised in clinical practice guidelines.

Sources: en.wikipedia.org

Frequently asked questions

What type of molecule is ipamorelin?

It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.

Which receptor does ipamorelin act on?

It acts as an agonist at the growth hormone secretagogue receptor, also known as the ghrelin receptor. Binding at pituitary somatotroph cells promotes growth hormone release.

How does it differ from other secretagogues?

Early studies report weaker effects on cortisol, prolactin, and appetite than compounds such as GHRP-6. The size of that difference in humans is not firmly established.

Ipamorelin 与 GHRP-6 有什么不同?

两者都是 GHS-R1a 激动剂,但 ipamorelin 在研究中显示出更高的生长激素释放选择性。早期资料显示它对皮质醇、催乳素与食欲的刺激弱于 GHRP-6。这些差异是相对程度,而非绝对区分。

Network